Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
IMP dehydrogenase 1 pseudogene (ENSG00000239392) is not a protein-coding gene but rather a pseudogene—specifically a non-functional copy related to the functional gene IMP dehydrogenase 1 (IMPDH1). This means it does not encode an active enzyme or receptor and is not a therapeutic target. IMP dehydrogenase 1 pseudogene (ENSG00000239392) is a non-protein-coding genomic sequence related by high homology to the functional gene IMP dehydrogenase 1. Pseudogenes like this originate through evolutionary processes such as gene duplication or retrotransposition but have lost the capacity to encode a functional protein, often due to disabling mutations or regulatory sequence loss[2][6][7]. Unlike its functional counterpart—in this case, IMPDH1, which catalyzes the rate-limiting step in de novo guanine nucleotide synthesis and is clinically relevant—the pseudogene does not produce protein and is not a therapeutic or diagnostic target[1][4]. Pseudogenes can sometimes have regulatory roles, such as acting as competitive endogenous RNAs (ceRNAs) or influencing gene expression through antisense transcripts, but specific functional evidence for IMP dehydrogenase 1 pseudogene (ENSG00000239392) is lacking and generally considered absent unless experimentally demonstrated[5][2]. Key distinctions: - The functional gene IMPDH1 encodes an enzyme, has disease relevance (e.g., retinitis pigmentosa), and can be a drug target[1][3][4]. - The pseudogene is *not functional* as an enzyme or receptor, does not participate in known therapeutic pathways, and is not considered a target in drug development or diagnostics[2][6][7]. Summary: IMP dehydrogenase 1 pseudogene (ENSG00000239392) is a non-functional genetic element corresponding to the protein-coding gene IMPDH1 but does not encode an active molecule and is not a valid target for therapeutic intervention. If the intention was to refer to the druggable enzyme, the correct target would be IMP dehydrogenase 1 (IMPDH1), not its pseudogene[1][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on IMP dehydrogenase 1 pseudogene.